Lupin surges on USFDA approval for Diclofenac Sodium

The company has received USFDA nod for anti-inflammatory drug Diclofenac Sodium

Shares of Lupin were up nearly 3% at Rs 1,875 after the pharma major received approval from the US Food & Drug Administration for anti-inflammatory drug Diclofenac Sodium.

Recently the pharma major said it has received approval from USFDA for Fenofibrate tablets in dosages of 160 mg and 54 mg. Fenofibrate is mainly used to reduce cholesterol levels in patients at risk of cardiovascular disease.

The stock has gained nearly 11% during August 2015 so far against nearly 7.5% decline in the Sensex.

The stock opened at Rs 1,845 and touched a high of Rs 1,895. At 11:50AM, over 950,000 shares were traded on both the stock exchanges.